Aurobac Therapeutics


AUROBAC THERAPEUTICS is a biopharmaceutical company founded as a joint venture by Boehringer Ingelheim, a leading research-driven biopharmaceutical company, the life science company Evotec SE and bioMérieux, a world leader in in vitro diagnostics, to create the next generation of products along with actionable diagnostics to fight AntiMicrobial Resistance (AMR).

AUROBAC plans to work to shift the strategy related to antibiotic treatment regimens, which now leans heavily on empirical approaches using broad-spectrum and unfocused medicines. The goal is to turn this into a precision approach, using new highly effective and targeted modalities, combined with rapid and actionable diagnostics to quickly identify pathogens and their resistance patterns, and supported by new economic models.

AUROBAC will cover the entire value chain of projects from R&D, including clinical development, to registration and commercialization.

AUROBAC is currently seeking to strengthen its product portfolio and is particularly interested in in-licensing or co-developing products developed to fight bacterial infections & AMR, with a focus on:

  • New and alternative modalities like e.g., phage lysins, therapeutic antibodies, etc.;
  • Novel target classes and mode of actions;
  • Host Immune-modulation approaches;
  • Products addressing high unmet medical needs;
  • Targeted modalities that can be combined with rapid and actionable diagnostics and that are supported by new economic models.

“The rise of AntiMicrobial resistance worldwide jeopardizes the prevention and treatment of life-threatening resistant bacterial infections, which are already killing 1.3 million people per year. AUROBAC has the remarkable ambition to become a leader in AMR innovation with a unique combination of the best capabilities of the three founding companies, Boehringer Ingelheim, Evotec and bioMérieux.

Our strategy is to develop and commercialize safe and effective drugs using selected diagnostic approaches, in order to cure efficiently infected patients with minimized risks of recurrence and limited impact on disseminating resistance.“

Florence Séjourné, CEO.

What is AMR?

AntiMicrobial resistance (AMR) has emerged as one of the principal public health problems of the 21st century that threatens the effective prevention and treatment of an ever-increasing range of infections caused by bacteria, parasites, viruses, and fungi no longer susceptible to the common medicines used to treat them.

The problem of AMR is especially urgent regarding antibiotic resistance in bacteria. Over several decades, to varying degrees, bacteria causing common or severe infections have developed resistance to each new antibiotic coming to market.

Faced with this reality, the need for action to avert a developing global crisis in health care is imperative, and innovation is required.

Source: National Library of Medicine

Latest News

AUROBAC THERAPEUTICS announces appointment of Martin Everett as Chief Scientific Officer

Commenting on the appointment, AUROBAC THERAPEUTICS CEO Florence Séjourné: “I am delighted that Martin is joining us. His incredibly strong knowledge and experience will be instrumental in helping us achieve our ambitious goals and making a profound impact in the field of antimicrobial resistance.”

Know more

AUROBAC THERAPEUTICS appoints Florence Séjourné as Chief Executive Officer

“Florence’s is an experienced biotech leader with outstanding strategic and operational acumen. The Board has great confidence in her to successfully set-up and lead AUROBAC.” said Frank Kalkbrenner, Ph.D., Co-Founder and Chairman of the Board of AUROBAC.

Know more

Boehringer Ingelheim, Evotec and bioMérieux launch AUROBAC THERAPEUTICS, a joint venture to fight AntiMicrobial Resistance

The resulting company, AUROBAC THERAPEUTICS SAS, will combine the best-of-best capabilities of the three founding companies towards developing a new precision medicine approach, from diagnosis to cure.

Know more

AUROBAC THERAPEUTICS is proud to be a member of the BEAM Alliance

This website is a temporary version; a complete new website will be available in 2023!

Legal Notice